237 related articles for article (PubMed ID: 18311487)
1. Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells.
Stoitzner P; Green LK; Jung JY; Price KM; Atarea H; Kivell B; Ronchese F
Cancer Immunol Immunother; 2008 Nov; 57(11):1665-73. PubMed ID: 18311487
[TBL] [Abstract][Full Text] [Related]
2. Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells.
Gerner MY; Mescher MF
J Immunol; 2009 Mar; 182(5):2726-37. PubMed ID: 19234167
[TBL] [Abstract][Full Text] [Related]
3. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.
Lugade AA; Moran JP; Gerber SA; Rose RC; Frelinger JG; Lord EM
J Immunol; 2005 Jun; 174(12):7516-23. PubMed ID: 15944250
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
5. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
[TBL] [Abstract][Full Text] [Related]
6. Murine melanoma-infiltrating dendritic cells are defective in antigen presenting function regardless of the presence of CD4CD25 regulatory T cells.
Ataera H; Hyde E; Price KM; Stoitzner P; Ronchese F
PLoS One; 2011 Mar; 6(3):e17515. PubMed ID: 21390236
[TBL] [Abstract][Full Text] [Related]
7. Isolation of immune cells from primary tumors.
Watkins SK; Zhu Z; Watkins KE; Hurwitz AA
J Vis Exp; 2012 Jun; (64):e3952. PubMed ID: 22733225
[TBL] [Abstract][Full Text] [Related]
8. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.
Schnurr M; Chen Q; Shin A; Chen W; Toy T; Jenderek C; Green S; Miloradovic L; Drane D; Davis ID; Villadangos J; Shortman K; Maraskovsky E; Cebon J
Blood; 2005 Mar; 105(6):2465-72. PubMed ID: 15546948
[TBL] [Abstract][Full Text] [Related]
9. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
10. Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy.
McDonnell AM; Lesterhuis WJ; Khong A; Nowak AK; Lake RA; Currie AJ; Robinson BW
Eur J Immunol; 2015 Jan; 45(1):49-59. PubMed ID: 25316312
[TBL] [Abstract][Full Text] [Related]
11. Twist1 promotes dendritic cell-mediated antitumor immunity.
Luo Y; Chen J; Liu M; Chen S; Su X; Su J; Zhao C; Han Z; Shi M; Ma X; Huang H
Exp Cell Res; 2020 Jul; 392(2):112003. PubMed ID: 32278689
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of melanoma growth after treatment with dendritic cells in a Tyr-SV40E murine model requires CD4+ T cells but not CD8+ T cells.
Milling SW; Sai T; Silvers WK; Mintz B
Melanoma Res; 2004 Dec; 14(6):555-62. PubMed ID: 15577330
[TBL] [Abstract][Full Text] [Related]
13. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
14. Prolonged antigen storage endows merocytic dendritic cells with enhanced capacity to prime anti-tumor responses in tumor-bearing mice.
Reboulet RA; Hennies CM; Garcia Z; Nierkens S; Janssen EM
J Immunol; 2010 Sep; 185(6):3337-47. PubMed ID: 20720209
[TBL] [Abstract][Full Text] [Related]
15. VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics.
Lund AW; Duraes FV; Hirosue S; Raghavan VR; Nembrini C; Thomas SN; Issa A; Hugues S; Swartz MA
Cell Rep; 2012 Mar; 1(3):191-9. PubMed ID: 22832193
[TBL] [Abstract][Full Text] [Related]
16. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
Tanaka Y; Koido S; Ohana M; Liu C; Gong J
J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
[TBL] [Abstract][Full Text] [Related]
17. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites.
Kobori H; Hashiguchi M; Piao J; Kato M; Ritprajak P; Azuma M
Immunology; 2010 Jul; 130(3):363-73. PubMed ID: 20141543
[TBL] [Abstract][Full Text] [Related]
19. T Cells Modified with CD70 as an Alternative Cellular Vaccine for Antitumor Immunity.
Lee SE; Shin AR; Sohn HJ; Cho HI; Kim TG
Cancer Res Treat; 2020 Jul; 52(3):747-763. PubMed ID: 32065848
[TBL] [Abstract][Full Text] [Related]
20. Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma.
Roberts EW; Broz ML; Binnewies M; Headley MB; Nelson AE; Wolf DM; Kaisho T; Bogunovic D; Bhardwaj N; Krummel MF
Cancer Cell; 2016 Aug; 30(2):324-336. PubMed ID: 27424807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]